At a glance
ClinicalIndex Comparison RecordN/ACompleted· 162 enrolled
Drug / intervention
metoclopramide +1 moredrug
Likely dose
metoclopramide 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-controlled Trial of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis in Patients Receiving High Dose Cisplatin in Routine Medical Practice
In Brief
A clinical study evaluating metoclopramide and placebo for Cancer. Completed, enrolled 162 participants across 1 site.
Detailed Summary
The objective of this study is to assess the efficacy and tolerability of metoclopramide added to standard antiemetic regimen for prophylaxis of cisplatin-induced emesis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesThailand
CollaboratorsSiriraj Hospital
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedMar 2010
Primary CompletionJun 2010
Study CompletionOct 2010
TodayJul 2026
First PostedMar 26, 2010
Enrollment StartApr 1, 2009
Primary CompletionJun 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.3 years ago
Interventions
metoclopramidedrug
ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
placebodrug
ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5